[A wireless ECG monitor based on ARM].

This paper presents a novel monitor which uses ARM controller AT91SAM7S64 as its main processor, LCM (Liquid Crystal Display Module) for displaying ECG waves, SD (Secure Digital memory) card for data storage and RF module PTR8000 for radio data transmission. This portable monitor boasts alarm function for abnormality and can provide dynamic ECG monitoring for patients.

[Study on apoptosis of lung tissue cells in patients with severe brain injury complicated with aspiration-induced lung injury].

OBJECTIVE: To investigate the role of apoptosis of pulmonary cells in aspiration induced lung injury in patients with severe brain injury with or without aspiration-induced lung injury. METHODS: The Glasgow scale (GCS) of 11 dead patients with severe closed brain injury was 3-8. There 11 cases were divided into aspiration-induced lung injury (AILI) and non-aspiration-induced lung injury (NAILI) groups. The plasma levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-8 (IL-8) were measured, and the ratio of apoptosis in lung tissue cells was also determined. RESULTS: The plasma levels of TNF-alpha and IL-8 in NAILI and AILI groups were (2.17+/-0.41)nug/L vs. (3.14+/-0.28)nug/L and (0.42+/-0.05)nug/L vs. (0.91+/-0.08) nug/L (P<0.05) respectively. Lung tissue cell apoptosis ratio was significantly higher in AILI group than NAILI group (P<0.01). CONCLUSION: TNF-alpha and IL-8 may induce apoptosis in lung tissues through different signaling pathway. During the early phase of aspiration-induced lung injury complicating severe closed brain injury, apoptosis in cells of lung tissue may play a role in the pathogenes.

[Study on defibrinogenasing enhancing the thrombolytic effect of urokinase on acute myocardial infarction].

OBJECTIVE: To investigate the thrombolytic effects and the security of combined therapy of defibrinogenase (DEF) and lower dose urokinase (UK) on patients with acute myocardial infarction (AMI). METHODS: Forty-five patients with AMI within 6 hours from the onset were divided into two groups, the combined therapy group (UK+DEF group, n=23) and the full dose UK group (UK group, n =22). The dosage of the UK in UK+DEF group was only the half of the full dos e UK group. In UK+DEF group, intravenous injection of 5 U DEF was preceded with intravenous infusion of UK, and after that, 5 U of DEF was infused intravenously in three separate times. Aspirin was prescribed for all patients. Coronary reperfusion was evaluated according to clinical criteria. The complication of bleeding was noted. Plasma fibrinogen (Fg) and D-dimer levels were determined before and after thrombolytic therapy. RESULTS: The age, body weight, time from onset, reperfusion rate, reinfarction rate, bleeding complications and the mortality during hospitalization were similar in both groups (P>0.05), and no severe bleeding was found. The reperfusion rate of UK+DEF group (69.56 percent) was comparable with that of UK group (68.18 percent), P>0.05. While the time to reperfusion of UK+DEF group was markedly shorten than that of UK group, it was (62.08+/-32.40) minutes vs. (80.00+/-39.14) minutes respectively (P<0.01). The plasma levels of D-dimer were similar and were elevated at the 6 hours after the beginning of thrombolytic therapy both in two groups (P<0.05). The plasma Fg level was declined obviously in UK+DEF group with a decrease in 58.46 percent, while it was slightly declined in UK group with a 16.78 percent decrease in percentage compared to those levels of pre-thrombolysis. CONCLUSION: The combination of DEF can enhance the thrombo lytic efficacy of UK, and can accelerate the lysis of coronary thrombus. The effect and the security of combination therapy are comparable to the full dose UK therapy.